Earlier this week, Accelrys, Inc. declared its purchase of Web-based Hit Explorer Operating System (HEOS) from drug manufacturing company, SCYNEXIS, Inc. This completed the contract entered into by both parties in 2011 for the marketing of HEOS using Accelrys’ Cheminformatics Suite of software applications.
The HEOS Software-as-a-Service (SaaS) platform induces better management and brings forth advanced research tools which provide celerity to drug development and discovery. These include biological assay results, advanced analytical tools and historical data access. Not only do these features come in a flexible and secure solution package, but are also immensely user-friendly and affordable.
Accelrys shall be able to ameliorate its research development procedures and also address a larger scientific forum using the HEOS package. Hence, market share proliferation and goodwill enhancement seem to be on the cards for the company through this integration.
The company has maintained a proactive stance with regard to escalating product standards and opting for technological advancements. In its first quarter financial results declared on May 3, 2012, the company reported a 64% annual hike in expenses accrued for product development to reach $0.38 million in the quarter. It is praiseworthy that Accelrys is wholeheartedly devoted to enhancing and developing its product portfolio even in times of clouded macro conditions.
However, there are companies which threaten Accelrys’ formidable industry position at all times. These include big players such as MSCI Inc. (MSCI - Snapshot Report), RealPage, Inc. (RP - Snapshot Report) and Guidewire Software, Inc. (GWRE - Snapshot Report).
The company currently retains a Zacks #2 Rank, which translates into a short-term ‘Buy’ rating. However, we presently maintain our ‘Neutral’ recommendation on the stock.